Role of Plasmapheresis and Extracorporeal Membrane Oxygenation in the Treatment of Leptospirosis Complicated with Pulmonary Hemorrhages

Abstract

Introduction Leptospirosis is an emerging infectious disease associated with multiorgan involvement and significant morbidity and mortality. Although pulmonary hemorrhage due to leptospirosis has a high fatality, specific treatment options are limited and their efficacy is not adequately proven. We opted to find out the current evidence on plasmapheresis and extracorporeal membrane oxygenation (ECMO) in pulmonary hemorrhages due to leptospirosis. Methods The first search was conducted in PubMed, OVID, Google Scholar, and Cochrane clinical trial registry using keywords “leptospirosis” OR “Leptospira” OR “Weil's disease” AND “plasmapheresis” OR “plasma exchange” AND “pulmonary hemorrhage” OR “alveolar hemorrhage” OR “lung hemorrhage” and the second search was done using keyword “leptospirosis” OR “Leptospira” OR “Weil's disease” AND “ECMO” OR “Extracorporeal membrane oxygenation.” The searches were not limited by study design or the date of publication. Only articles written in English were reviewed. Although we intended to include only clinical trials, it was decided later to include other information such as case reports and case series which addressed these treatment modalities. Two authors selected articles independently in a blinded manner using a set of inclusion and exclusion criteria and discrepancies were solved after discussions. Results The information found was very limited. This included one clinical trial which showed a significant survival benefit with plasmapheresis but the study design had many limitations. Two case reports described the benefit of plasmapheresis in severe leptospirosis with pulmonary hemorrhages. There were eight case reports where ECMO was performed and out of all only one patient has died. One retrospective study on patients with severe leptospirosis mentioned that four out of five patients with pulmonary hemorrhages survived after being treated with ECMO. Conclusions Current evidence is insufficient to recommend the routine use of plasmapheresis or ECMO for patients presenting with pulmonary hemorrhages due to leptospirosis. ECMO may be a promising mode of treatment in acute respiratory failure in leptospirosis related pulmonary hemorrhages. These treatment modalities, however, can be applied based on the availability of resources and expertise at the discretion of the clinician in charge, considering patient related factors such as cardiovascular stability and derangement of coagulation profile. Clinical trials conducted adhering to standard procedures are urgently required to establish the efficacy of these treatment modalities.

Optimizing the Intensive Care Treatment of Severe and Complicated Plasmodium falciparum Malaria in Nonimmune Patients

“…We evaluated the efficacy of extracorporeal hemocorrection methods in severe malaria by determining the asexual parasite clearance. The parasite clearance estimator (PCE) developed by the Worldwide Antimalarial Resistance Network (WWARN) seemed to be an accurate and reliable method [ 14 ]. Out of the overall 72 ICU patients from the two groups, data from 54 ICU patients were suitable for estimation of parasite clearance: the main group had 38 (70%) patients while the control group had 16 (30%) patients.…”

Plasmapheresis reduces cytokine and immune cell levels in COVID-19 patients with acute respiratory distress syndrome (ARDS)

“… 7 However, the evidence to date is insufficient to recommend the routine use of plasmapheresis to correct the hypoxemia, which can lead to multiorgan dysfunction due to advanced modes of treatment. 38 However, plasmapheresis may be used based on disease severity and the availability of resources. Importantly, we demonstrate that plasmapheresis improves some clinical variables in our patients such as the PaO 2 /FiO 2 ratio although we cannot confirm a significant survival benefit due to a lack of control subjects.…”

Recreational ‘mud fever’: Leptospira interrogans induced diffuse alveolar hemorrhage and severe acute respiratory distress syndrome in a U.S. Navy seaman following ‘mud-run’ in Hawaii

“…Use of ECMO in leptospirosis had been reported only thrice through the year 2010 but 15 times (including this case) since 2015 [[17], [18], [19]]. The case described here is the second report of use of ECMO for leptospirosis in the United States, both contracted outside of the contiguous United States.…”